课题基金 / 基金详情

Overcoming stromal barriers to therapeutics in pancreas cancer

Overcoming stromal barriers to therapeutics in pancreas cancer
克服胰腺癌治疗的基质障碍
批准号:
8891383
负责人:
Sunil R Hingorani
金额:
$50.62万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-22 至 2016-07-31

项目摘要

项目成果

Sunil R Hingorani的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):胰腺导管腺癌(PDA)是一种罕见的致死性疾病,在所有癌症中1年和5年死亡率最高。无法早期发现疾病,加上对化学和放射治疗的多重内在抗性机制,导致了PDA的极端致命性。在开发有效的靶向治疗胰腺癌的挑战是高度的数值(非整倍体)和结构(非互易位)染色体不稳定性。伴随并记录疾病进展的强大的纤维炎症反应或结缔组织增生给治疗疾病带来了额外的挑战,同时也为对抗PDA提供了新的潜在靶点和方法。我们最近描述了一些胰腺癌中促结缔组织增生反应的关键因素,以及这些因素促进和维持新生肿瘤的机制。这些成分包括肿瘤相关巨噬细胞、间质成纤维细胞和多种类型的免疫抑制细胞,这些细胞在侵袭前疾病的早期阶段侵入并包围前体导管病变;一种致密的间质胶原和蛋白多糖基质,似乎抑制血管生成并损害肿瘤血管;以及极高的肿瘤内流体压力。因此,小分子的传递、扩散和对流都受到基质环境的严重限制,这些不同的因素共同为胰腺癌的发展创造了一个避难所。在这一建议中,我们将首先研究不同干预措施破坏胰腺癌基质和改善灌注的能力,以增强化疗药物的递送和疗效。我们还将测试针对间质室和上皮室的组合策略的能力,以对这种致命疾病产生临床显着影响。
英文摘要
DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDA) is an unusually lethal disease with the highest 1-year and 5- year mortality rates of any cancer. An inability to detect the disease early together with multiple mechanisms of intrinsic resistance to chemical and radiotherapies contribute to the extreme lethality of PDA. Compounding the challenge in developing effective targeted therapies against pancreas cancer is the high degree of both numerical (aneuploidy) and structural (non-reciprocal translocations) chromosomal instability. The robust fibroinflammatory response, or desmoplasia, that accompanies and chronicles disease progression presents additional challenges to treating the disease, while also providing novel potential targets and approaches to combating PDA. We have recently characterized a number of critical elements of the desmoplastic reaction in pancreas cancer and the mechanisms by which these components promote and sustain nascent neoplasms. These components include tumor- associated macrophages, stromal fibroblasts and multiple types of immunosuppressive cells that invade and surround precursor ductal lesions from the earliest stages of preinvasive disease; a dense stromal collagen and proteoglycan matrix that appears to suppress angiogenesis and compromise tumor vascularity; and extremely high intratumoral fluid pressures. Thus, the delivery, diffusion and convection of small molecules are all critically limited by the stromal environment and together these various factors conspire to create a sanctuary for pancreas cancer progression. In this proposal, we will investigate first the ability of distinct interventions to disrupt the stromal matrix and improve perfusion in pancreas cancer to enhance the delivery and efficacy of chemotherapeutic agents. We will also test the ability of combining strategies directed against the stromal and epithelial compartments to make a clinically significant impact against this lethal disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER
Stopping PDA progression using inhibitors of CSC dissemination and immunotherapy
Investigating the metastatic drive in pancreas cancer
  • 批准号:
    10601457
  • 项目类别:
  • 资助金额:
    $21.62万
  • 财政年份:
    2018
  • 负责人:
    Sunil R Hingorani
  • 依托单位:
海外基金